Will BridgeBio's quarterly cash burn exceed $120M in either Q1 or Q2 2026?

FY2025 average was ~$112M/quarter with a declining trajectory. Management guided burn holds steady in 2026 and declines by year-end. However, Q1 and Q2 may see temporary increases from pipeline launch preparations (encaleret pre-NDA activities, infigratinib filing, Attruby sales team expansion). The $120M threshold is only ~7% above the FY2025 average. With Attruby revenue growing (offsetting some cash outflow), net cash consumption may actually decline even if gross spending increases. But timing of revenue recognition vs. cash collection can create quarterly volatility.

The question asks about 'either Q1 or Q2' — a two-quarter window doubles the opportunity for a single quarter to exceed $120M. Quarterly cash flow is inherently lumpy due to timing of milestone payments, convertible interest, and working capital changes. Even with declining average burn, one quarter could spike above $120M on timing effects alone. The CAPITAL_DEPLOYMENT = DISCIPLINED signal suggests management is cost-conscious, but the simultaneous demands of commercial expansion and pipeline launches create countervailing cost pressure.

Revenue growth is the most important offset factor. If Attruby reaches $175M+ in Q1 (68% probability from revenue market), the revenue offset to gross spending significantly narrows net burn. The path from -$446M annual burn to positive cash flow requires this trajectory. The Atomic Auditor noted cash burn was declining quarter-over-quarter in FY2025. Management's track record of EXCEEDING operational expectations extends to cost management. The $120M threshold may not be crossed if revenue growth outpaces spending growth.

Pipeline launch costs are real and typically front-loaded. BridgeBio is simultaneously expanding Attruby's sales team, building global commercial infrastructure, and preparing three NDA submissions. The conflict between Stress Scanner (STRETCHED) and Atomic Auditor (implied adequate) reflects genuine uncertainty about whether costs will outrun revenue growth in the near-term. Q1 is often a higher spending quarter due to annual compensation resets and new-year budgets. The two-quarter window and $120M threshold (close to the FY2025 average) make this roughly a coin-flip.

The $120M threshold for net cash used in operations is specific to operating cash flow, which differs from OpEx. Working capital timing (accounts receivable from Attruby sales, accounts payable from R&D) can create significant quarterly variation. A single large clinical milestone payment or commercial infrastructure investment could push one quarter above $120M even if the trend is declining. Management stated burn holds steady in 2026 — steady at $112M/quarter is close to $120M with normal variation.

Management's explicit guidance that burn 'holds steady and declines by year-end' suggests they expect H1 to be near the FY2025 average (~$112M) before declining in H2. If the guidance is accurate, the probability of exceeding $120M in either Q1 or Q2 depends on the variance around $112M. Normal quarterly variance for a company of this size is roughly +/-10-15%, putting the $120M threshold within the upper range but not certainly above. Management has been reliable on operational guidance (EXCEEDING execution).

Average was $112M declining. $120M is 7% above average. Pipeline launch prep adds costs but revenue growth offsets. Management guided steady. Two-quarter window adds probability. Close to coin-flip, slightly below 50%.

Management execution has been strong on cost discipline. Revenue growth will increasingly offset gross spending. The declining trajectory from FY2025 suggests burn is heading lower, not higher. The $120M threshold requires a reversal of the declining trend, which is unlikely given management guidance.

The two-quarter window and normal quarterly variation mean there is a meaningful probability that one quarter hits $120M even if the average continues to decline. Cash flow timing effects (milestones, working capital) can create spikes. But management's guidance and declining trajectory argue against sustained burn increases. Probability just below 50%.